COMPARISON OF THE EFFECTS OF ERECTOR SPINAE PLANE (ESP) BLOCK AND QUADRO İLİAC PLANE (QIP) BLOCK ON POSTOPERATIVE OPIOID CONSUMPTION AND PAIN IN LUMBAR SPINAL SURGERY

September 29, 2026 updated by: SINEM SARI, Aydin Adnan Menderes University

COMPARISON OF THE EFFECTS OF ERECTOR SPINAE PLANE (ESP) BLOCK AND QUADRO ILIAC PLANE (QIP) BLOCK ON POSTOPERATIVE OPIOID CONSUMPTION AND PAIN IN LUMBAR SPINAL SURGERY

COMPARISON OF THE EFFECTS OF ERECTOR SPINAE PLANE (ESP) BLOCK AND QUADRO İLİAC PLANE (QIP) BLOCK ON POSTOPERATIVE OPIOID CONSUMPTION AND PAIN IN LUMBAR SPINAL SURGERY

Study Overview

Detailed Description

The study is designed as a double-blind, prospective, randomized controlled trial. Regarding blinding, the healthcare personnel responsible for monitoring postoperative pain will be unaware of whether the patients received an ESP block or a QIP block. Patient randomization was planned using a computer-based system. Following the operation, once patients are transferred to the postoperative recovery room, their pain levels will be assessed and recorded using the Numeric Rating Scale (NRS) at the following time points: 30 minutes, and 1, 6, 12, and 24 hours. In the ward, patients will receive tramadol via PCA and paracetamol every eight hours. Hourly NRS monitoring is planned during the patient's follow-up in the ward. If the NRS score reaches 4 or higher during this period, 75 mg of diclofenac sodium will be administered intramuscularly, and the number of self-administered bolus doses via PCA (Patient-Controlled Analgesia) within the first 24 hours will be recorded. Opioid consumption and pain levels (via NRS scores) will be evaluated at the 24th postoperative hour for patients in both the ESP and QIP block groups. Additionally, the patients' hemodynamic parameters will be recorded at these time intervals.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Aydin, Turkey (Türkiye), 09100
        • Aydin Adnan Menderes Üniversitesi Tip Fakültesi Hastanesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Undergoing elective lumbar spinal surgery
  2. ASA I-III
  3. Aged 18-75 years Exclusion Criteria: - 1. Refusal at the time of enrollment 2. Request to withdraw from the study 3. Inability to provide informed consent 4. Emergency surgery 5. Bleeding diathesis 6. Presence of contraindications to the local anesthetic (LA) agents used in this study 7. Chronic opioid use 8. Psychiatric disorders 9. Presence of infection at the injection site

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ESP BLOCK

An 11-point Numerical Rating Scale (NRS), where 0 indicated no pain and 10 represented the worst pain imaginable, was used to assess patients' pain levels.

The total number of patient-controlled analgesia (PCA) bolus doses delivered within the first 24 hours will record

All patients in the ward will be administered intravenous paracetamol every 8 hours, and intramuscular diclofenac sodium (75 mg) if the NRS score is 4 or higher.

Other Names:
  • DİCLOFENAK SODYUM
  • PCA İLE TRAMADOL
  • PARASETAMOL
Experimental: QIP BLOCK

An 11-point Numerical Rating Scale (NRS), where 0 indicated no pain and 10 represented the worst pain imaginable, was used to assess patients' pain levels.

The total number of patient-controlled analgesia (PCA) bolus doses delivered within the first 24 hours will record

All patients in the ward will be administered intravenous paracetamol every 8 hours, and intramuscular diclofenac sodium (75 mg) if the NRS score is 4 or higher.

Other Names:
  • DİCLOFENAK SODYUM
  • PCA İLE TRAMADOL
  • PARASETAMOL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To compare the effects of the Quadro İliac Plane Block and the Erector Spinae Plane (ESP) Block on postoperative opioid consumption in lumbar spinal surgeries
Time Frame: 24 hour

All patients will be administered tramadol via PCA, and the amount of tramadol consumed will be assessed at the end of the 24-hour postoperative period.

24 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To compare the effects of the Quadro iliac (Qıp) block and the Erector Spinae Plane (ESP) block on postoperative pain in lumbar spinal surgeries
Time Frame: 12th hour

The NRS score will be assessed on a scale of 0 to 10, with 0 representing the lowest and 10 the highest value; patients will be asked to provide a rating at the 12th hour.

12th hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

August 3, 2026

First Submitted That Met QC Criteria

September 29, 2026

First Posted (Actual)

October 1, 2026

Study Record Updates

Last Update Posted (Actual)

October 1, 2026

Last Update Submitted That Met QC Criteria

September 29, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe